BioSpace News Archive

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the second quarter ended June 30, 2023, after the market closes on Thursday, July 27, 2023.

Vistagen (Nasdaq: VTGN) today announced that the Canadian Intellectual Property Office (CIPO) issued a Notice of Allowance for a patent related to the use of AV-101 for reduction of dyskinesia (sudden uncontrolled movements) induced by the administration of levodopa (L-Dopa), the most commonly prescribed medication for treatment of Parkinson’s disease (PD).

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the market close on Wednesday, August 9th, 2023.

Thermo Fisher Scientific Inc., the world leader in serving science, announced Jenny Johnson, president and chief executive officer of Franklin Resources, Inc., has been elected to its board of directors.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on October 13, 2023, to shareholders of record as of September 15, 2023.

Locust Walk,a global investment bank that integrates corporate development strategy and execution with capital raising for innovative life science companies

Astellas Pharma Inc. today announced the European Medicines Agency (EMA) has accepted for regulatory review the company’s marketing authorization application (MAA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive.

Nona Biosciences announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors.

Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT) today announced the pricing of its upsized initial public offering of 5,312,500 shares of its Series A common stock at a public offering price of $16.00 per share.

Globus Medical, Inc., a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023.